EXAI — Exscientia Share News
0.000.00%
Last trade - 00:00HealthcareSpeculativeMid Cap
- $1.24bn
- $900.27m
- £20.08m
Exscientia PLC expected to post a loss of 35 cents a share - Earnings Preview
Brief: GT Apeiron Announces Enrollment Of First Patient In Phase 1/2 'Elucidate' Clinical Trial Of Cdk7 Inhibitor, Gtaexs617, In Advanced Solid Tumors
Exscientia PLC expected to post a loss of 43 cents a share - Earnings Preview
Exscientia PLC reports results for the quarter ended in December - Earnings Summary
Exscientia PLC expected to post a loss of 28 cents a share - Earnings Preview
Exscientia up on expansion of its cancer treatment pipeline
Brief: Exscientia Announces Expansion Of Its Precision Oncology Pipeline
Exscientia up on deal to develop its AI-driven platform for blood cancer patients
Brief: Exscientia Begins Human Trials For Bristol Myers In-Licensed PKC Theta Inhibitor EXS4318
Brief: Exscientia Presents Novel Immuno-Oncology Biomarker For EXS-21546 At The ESMO I-O Annual Congress
Brief: Exscientia PLC Posts Qtrly Loss Per Share of $0.32
Brief: Exscientia And MD Anderson Launch Strategic Collaboration To Leverage Ai In Developing Novel Oncology Treatments
Exscientia PLC expected to post a loss of 32 cents a share - Earnings Preview
Brief: Exscientia Presents Novel Patient Stratification And Biomarker Data For GTAEXS-617 At The 34Th EORTC-NCI-AACR Annual Symposium
Exscientia PLC reports results for the quarter ended in June - Earnings Summary
Exscientia PLC expected to post a loss of 28 cents a share - Earnings Preview
Exscientia PLC reports results for the quarter ended in March - Earnings Summary
Exscientia PLC expected to post a loss of 31 cents a share - Earnings Preview
Exscientia PLC reports results for the quarter ended in December - Earnings Summary